You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethocarbamol
Accession NumberDB00423  (APRD01102)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206)
Structure
Thumb
Synonyms
(RS)-2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
Delaxin
Methocarbamol
Méthocarbamol
Methocarbamolum
Metocarbamol
Metocarbamolo
Robaxin
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methocarbamol Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousUnivet Pharmaceuticals Ltd.1988-12-31Not applicableCanada
Methocarbamol OmegaLiquid100 mgIntramuscular; IntravenousOmega Laboratories Ltd2003-07-28Not applicableCanada
PMS-methocarbamol Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousPharmascience Inc1990-12-312016-10-28Canada
Robaximol Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousMontreal Veterinary Products Inc.1989-12-31Not applicableCanada
RobaxinInjection100 mg/mLIntramuscular; IntravenousWest Ward Pharmaceutical Corp.1959-06-16Not applicableUs
RobaxinTablet, film coated750 mg/1OralEndo Pharmaceuticals, Inc.2011-08-18Not applicableUs
RobaxinTablet, film coated750 mg/1OralSTAT Rx USA LLC2003-01-20Not applicableUs
RobaxinTablet500 mg/1OralREMEDYREPACK INC.2012-08-162016-10-13Us
RobaxinTablet, film coated500 mg/1OralEndo Pharmaceuticals, Inc.2012-05-15Not applicableUs
RobaxinTablet, film coated750 mg/1OralPd Rx Pharmaceuticals, Inc.2003-01-20Not applicableUs
Robaxin Inj 100mg/mlLiquid100 mgIntramuscular; IntravenousAyerst Laboratories1992-12-311997-08-15Canada
Robaxin Injectable Liq 100mg/mlLiquid100 mgIntramuscular; IntravenousWyeth Ayerst Canada Inc.1996-10-252000-03-07Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethocarbamolTablet750 mg/1OralCardinal Health2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralREMEDYREPACK INC.2015-06-022016-11-30Us
MethocarbamolTablet500 mg/1Oralbryant ranch prepack2010-03-01Not applicableUs
MethocarbamolTablet750 mg/1OralAmerican Health Packaging2013-06-26Not applicableUs
MethocarbamolTablet750 mg/1OralBlenheim Pharmacal, Inc.2016-01-07Not applicableUs
MethocarbamolTablet, film coated500 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-02-20Not applicableUs
MethocarbamolTablet500 mg/1OralQualitest Pharmaceuticals2003-01-29Not applicableUs
MethocarbamolInjection, solution1000 mg/10mLIntramuscular; IntravenousAuro Medics Pharma Llc2016-05-27Not applicableUs
MethocarbamolTablet500 mg/1OralPd Rx Pharmaceuticals, Inc.2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralREMEDYREPACK INC.2016-11-30Not applicableUs
MethocarbamolTablet750 mg/1OralNorthwind Pharmaceuticals, LLC2014-09-23Not applicableUs
MethocarbamolTablet500 mg/1OralA S Medication Solutions Llc2000-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralBlenheim Pharmacal, Inc.2014-01-13Not applicableUs
MethocarbamolTablet500 mg/1OralGolden State Medical Supply, Inc.2015-01-13Not applicableUs
MethocarbamolTablet500 mg/1OralDispensing Solutions, Inc.2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralAvera Mc Kennan Hospital2015-09-30Not applicableUs
MethocarbamolTablet500 mg/1OralPd Rx Pharmaceuticals, Inc.2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralKAISER FOUNDATION HOSPITALS2011-06-06Not applicableUs
MethocarbamolTablet500 mg/1OralA S Medication Solutions2000-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralLake Erie Medical DBA Quality Care Products LLC2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralREMEDYREPACK INC.2012-03-122016-10-26Us
MethocarbamolTablet500 mg/1OralREMEDYREPACK INC.2013-09-272016-11-30Us
MethocarbamolTablet500 mg/1OralH.J. Harkins Company, Inc.1987-11-01Not applicableUs
MethocarbamolTablet500 mg/1OralPd Rx Pharmaceuticals, Inc.2010-03-01Not applicableUs
MethocarbamolTablet750 mg/1OralAidarex Pharmaceuticals LLC2000-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralPreferred Pharmaceuticals, Inc.2010-08-06Not applicableUs
MethocarbamolTablet750 mg/1OralClinical Solutions Wholesale, Llc2013-03-20Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralMajor Pharmaceuticals1976-08-11Not applicableUs
MethocarbamolTablet500 mg/1OralNu Care Pharmaceuticals, Inc.2013-03-20Not applicableUs
MethocarbamolTablet500 mg/1OralSolco Healthcare US LLC2013-01-15Not applicableUs
MethocarbamolTablet500 mg/1OralLiberty Pharmaceuticals, Inc.2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralA S Medication Solutions2013-03-20Not applicableUs
MethocarbamolTablet750 mg/1OralSTAT Rx USA LLC1987-11-01Not applicableUs
MethocarbamolTablet750 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-03-20Not applicableUs
MethocarbamolTablet750 mg/1OralAv Pak2014-10-20Not applicableUs
MethocarbamolTablet500 mg/1OralPhysicians Total Care, Inc.2009-07-21Not applicableUs
MethocarbamolTablet500 mg/1OralRebel Distributors Corp.2000-01-01Not applicableUs
MethocarbamolTablet, film coated750 mg/1OralDIRECT RX2015-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralAphena Pharma Solutions Tennessee, Inc.2000-01-01Not applicableUs
MethocarbamolTablet, film coated750 mg/1OralVirtus Pharmaceuticals2013-12-15Not applicableUs
MethocarbamolTablet750 mg/1OralREMEDYREPACK INC.2015-12-24Not applicableUs
MethocarbamolTablet750 mg/1OralCardinal Health2007-07-09Not applicableUs
MethocarbamolTablet500 mg/1OralREMEDYREPACK INC.2013-01-192016-10-25Us
MethocarbamolTablet750 mg/1Oralbryant ranch prepack2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralKeltman Pharmaceuticals Inc.2007-07-25Not applicableUs
MethocarbamolTablet, film coated500 mg/1OralCarilion Materials Management2013-12-15Not applicableUs
MethocarbamolTablet, film coated750 mg/1OralAphena Pharma Solutions Tennessee, Llc2014-02-20Not applicableUs
MethocarbamolTablet750 mg/1OralQualitest Pharmaceuticals2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralSt. Mary's Medical Park Pharmacy2013-03-20Not applicableUs
MethocarbamolTablet500 mg/1OralPd Rx Pharmaceuticals, Inc.2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralREMEDYREPACK INC.2014-01-08Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions Llc2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralBlenheim Pharmacal, Inc.2014-01-22Not applicableUs
MethocarbamolTablet750 mg/1OralGolden State Medical Supply, Inc.2015-01-13Not applicableUs
MethocarbamolTablet750 mg/1OralContract Pharmacy Services Pa2000-01-01Not applicableUs
MethocarbamolTablet, film coated500 mg/1OralVirtus Pharmaceuticals2015-07-13Not applicableUs
MethocarbamolTablet750 mg/1OralREMEDYREPACK INC.2012-03-27Not applicableUs
MethocarbamolTablet750 mg/1OralKAISER FOUNDATION HOSPITALS2011-06-07Not applicableUs
MethocarbamolTablet500 mg/1OralA S Medication Solutions2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralLake Erie Medical DBA Quality Care Products LLC2013-03-20Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions2013-03-20Not applicableUs
MethocarbamolTablet500 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2011-11-16Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralMajor Pharmaceuticals1976-08-18Not applicableUs
MethocarbamolTablet750 mg/1OralNu Care Pharmaceuticals, Inc.2013-03-20Not applicableUs
MethocarbamolTablet750 mg/1OralSolco Healthcare US LLC2013-01-15Not applicableUs
MethocarbamolTablet750 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralClinical Solutions Wholesale2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralAidarex Pharmaceuticals LLC2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralHetero Drugs Limited Unit III2009-11-06Not applicableUs
MethocarbamolTablet750 mg/1OralPreferred Pharmaceuticals, Inc.2014-11-25Not applicableUs
MethocarbamolTablet500 mg/1OralWest Ward Pharmaceuticals Corp2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralAmerican Health Packaging2013-05-062015-12-29Us
MethocarbamolTablet750 mg/1OralDIRECT RX2015-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralWatson Laboratories, Inc.1987-11-01Not applicableUs
MethocarbamolTablet500 mg/1OralA S Medication Solutions2013-03-20Not applicableUs
MethocarbamolTablet500 mg/1OralSTAT Rx USA LLC1987-11-01Not applicableUs
MethocarbamolTablet750 mg/1OralRed Pharm Drug, Inc.2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralUnit Dose Services2000-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralPhysicians Total Care, Inc.2003-07-14Not applicableUs
MethocarbamolTablet750 mg/1OralRebel Distributors Corp.1976-08-18Not applicableUs
MethocarbamolTablet750 mg/1OralProficient Rx LP2013-03-20Not applicableUs
MethocarbamolTablet500 mg/1OralAphena Pharma Solutions Tennessee, Inc.2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralCardinal Health2007-07-03Not applicableUs
MethocarbamolTablet500 mg/1OralCamber Pharmaceuticals, Inc.2013-03-20Not applicableUs
MethocarbamolTablet750 mg/1Oralbryant ranch prepack2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralKeltman Pharmaceuticals Inc.2009-05-08Not applicableUs
MethocarbamolTablet750 mg/1OralCardinal Health2013-06-26Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-01-09Not applicableUs
MethocarbamolTablet750 mg/1OralAphena Pharma Solutions Tennessee, Llc2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralREMEDYREPACK INC.2015-06-22Not applicableUs
MethocarbamolTablet500 mg/1OralA S Medication Solutions Llc2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralSTAT Rx USA LLC2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralREMEDYREPACK INC.2014-10-13Not applicableUs
MethocarbamolTablet750 mg/1OralContract Pharmacy Services Pa2010-03-01Not applicableUs
MethocarbamolTablet, film coated750 mg/1OralVirtus Pharmaceuticals2015-07-13Not applicableUs
MethocarbamolTablet500 mg/1OralREMEDYREPACK INC.2012-05-17Not applicableUs
MethocarbamolTablet500 mg/1OralKAISER FOUNDATION HOSPITALS2015-06-04Not applicableUs
MethocarbamolTablet500 mg/1OralA S Medication Solutions2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralRebel Distributors Corp2010-03-01Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions2013-03-20Not applicableUs
MethocarbamolTablet750 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-11-16Not applicableUs
MethocarbamolTablet500 mg/1OralPreferred Pharmaceuticals, Inc.2014-11-18Not applicableUs
MethocarbamolTablet750 mg/1OralWest Ward Pharmaceuticals Corp2000-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralBlenheim Pharmacal, Inc.2000-01-01Not applicableUs
MethocarbamolTablet, film coated500 mg/1OralNu Care Pharmaceuticals, Inc.2015-07-13Not applicableUs
MethocarbamolTablet750 mg/1OralMedsource Pharmaceuticals2013-01-15Not applicableUs
MethocarbamolTablet500 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
MethocarbamolTablet, film coated500 mg/1OralGolden State Medical Supply, Inc.2014-02-20Not applicableUs
MethocarbamolTablet750 mg/1OralLake Erie Medical & Surgical Supply DBA Quality Care Products LLC2000-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralHetero Drugs Limited Unit III2009-11-06Not applicableUs
MethocarbamolTablet750 mg/1OralREMEDYREPACK INC.2013-04-022016-03-12Us
MethocarbamolTablet500 mg/1OralProficient Rx LP2013-03-20Not applicableUs
MethocarbamolTablet500 mg/1OralAmerican Health Packaging2013-06-26Not applicableUs
MethocarbamolTablet750 mg/1OralAmerican Health Packaging2013-05-062015-12-29Us
MethocarbamolTablet750 mg/1OralProficient Rx LP2013-01-15Not applicableUs
MethocarbamolTablet750 mg/1OralWatson Laboratories, Inc.1987-11-01Not applicableUs
MethocarbamolInjection, solution100 mg/mLIntramuscular; IntravenousGENERAL INJECTABLES AND VACCINES, INC.2016-07-18Not applicableUs
MethocarbamolTablet750 mg/1OralPd Rx Pharmaceuticals, Inc.2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralRed Pharm Drug, Inc.2013-03-20Not applicableUs
MethocarbamolTablet750 mg/1OralUnit Dose Services2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralCardinal Health2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralPd Rx Pharmaceuticals, Inc.1987-11-01Not applicableUs
MethocarbamolTablet750 mg/1OralCamber Pharmaceuticals, Inc.2013-03-20Not applicableUs
MethocarbamolTablet500 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralPreferred Pharmaceuticals, Inc.2010-08-06Not applicableUs
MethocarbamolTablet500 mg/1OralClinical Solutions Wholesale, Llc2013-03-20Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions2000-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-01-29Not applicableUs
MethocarbamolTablet, film coated750 mg/1OralProficient Rx LP2015-07-13Not applicableUs
MethocarbamolTablet500 mg/1OralAphena Pharma Solutions Tennessee, Llc2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralH.J. Harkins Company, Inc.1987-11-01Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions Llc2000-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralSTAT Rx USA LLC2000-01-01Not applicableUs
MethocarbamolTablet500 mg/1OralDIRECT RX2015-01-01Not applicableUs
MethocarbamolInjection, solution100 mg/mLIntramuscular; IntravenousMylan Institutional LLC2014-12-05Not applicableUs
MethocarbamolTablet, film coated500 mg/1OralVirtus Pharmaceuticals2013-12-15Not applicableUs
MethocarbamolTablet750 mg/1OralClinical Solutions Wholesale2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralKAISER FOUNDATION HOSPITALS2008-08-02Not applicableUs
MethocarbamolTablet500 mg/1OralA S Medication Solutions2003-01-29Not applicableUs
MethocarbamolTablet500 mg/1OralRebel Distributors Corp2010-03-01Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions2013-03-20Not applicableUs
MethocarbamolTablet500 mg/1OralAv Pak2014-10-20Not applicableUs
MethocarbamolTablet, film coated750 mg/1OralGolden State Medical Supply, Inc.2014-02-20Not applicableUs
MethocarbamolTablet500 mg/1OralLake Erie Medical DBA Quality Care Products LLC2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralDispensing Solutions, Inc.2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralPreferred Pharmaceuticals Inc.2015-08-20Not applicableUs
MethocarbamolTablet750 mg/1OralPd Rx Pharmaceuticals, Inc.2000-01-01Not applicableUs
MethocarbamolTablet750 mg/1OralA S Medication Solutions2003-01-29Not applicableUs
MethocarbamolTablet750 mg/1OralBlenheim Pharmacal, Inc.2014-01-22Not applicableUs
MethocarbamolTablet500 mg/1OralPreferred Pharmaceuticals, Inc.2016-05-23Not applicableUs
MethocarbamolTablet500 mg/1OralREMEDYREPACK INC.2011-07-122016-03-17Us
MethocarbamolTablet750 mg/1OralA S Medication Solutions Llc2000-01-01Not applicableUs
RobaxinTablet, film coated750 mg/1OralDIRECT RX2016-02-03Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RobaxinTablet500 mgOralPfizer Consumer Healthcare A Division Of Pfizer Canada Inc1958-12-31Not applicableCanada
Robaxin 750Tablet750 mgOralPfizer Consumer Healthcare A Division Of Pfizer Canada Inc1993-12-31Not applicableCanada
Unapproved/Other Products Not Available
International Brands
NameCompany
BolaxinYing Yuan
CarbaflexPaill
DelaxinNot Available
DoloVisanDr.Kade Pharmaceutische Fabrik
FubaxinGrape King
LumirelaxJuvise
MetocarbamolAZ Pharma
MioflexLabinco
MiorelCheminter
MusxanPharmasant
OrtotonRecordati
RebamolWinston
Robaxin-750Pfizer
RobinaxKhandelwal
SinaxarArmofar
TaspanHonten
Brand mixtures
NameLabellerIngredients
A.S.A. With Methocarbamol Night-time Extra StrengthPharmetics (2011) Inc
Acetaminophen 325mg + Methocarbamol 400mg CapletsMarcan Pharmaceuticals Inc
Acetaminophen 500mg + Methocarbamol 400mg Extra Strength CapletsInternational Pharmaceutical Generics Ltd
Advil Back PainPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Analgesic and Muscle RelaxantPharmascience Inc
Analgesic and Muscle Relaxant CapletsTeva Canada Limited
Aspirin BackacheBayer Inc Consumer Care
Aspirin Night-timeBayer Inc Consumer Care
Axacet-C1/8Technilab Pharma Inc.
Axisal-C1/8Technilab Pharma Inc.
AxumTeva Canada Limited
Dodd's Back-ease Muscle Spasm and Back Pain ReliefStella Pharmaceutical Canada Inc.
Dodd's Extra Strength Back-easeStella Pharmaceutical Canada Inc.
Douleurs Musculaires Et Les Courbatures Extra Fort/muscle and Back Pain Relief Extra StrengthProdemdis Enr.
Extra Strength Aspirin BackacheBayer Inc Consumer Care
Extra Strength Back PainPharmetics (2011) Inc
Extra Strength Body Pain NightPharmetics (2011) Inc
Extra Strength Muscle & Back Pain Asa 500 Mg Methocarbamol 400 Mg & Acetylsalicylic Acid 500 mgVita Health Products Inc
Extra Strength Muscle & Back Pain ReliefVita Health Products Inc
Extra Strength Muscle & Back Pain Relief With AsaVita Health Products Inc
Extra Strength Tylenol Back PainMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Extra Strength Tylenol Body Pain NightMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Ibuprofen+methocarbamol CapletsInternational Pharmaceutical Generics Ltd
MethoxacetTeva Canada Limited
Methoxacet Extra StrengthTeva Canada Limited
Methoxacet-C 1/8Teva Canada Limited
MethoxisalRougier Pharma Division Of Ratiopharm Inc
Methoxisal Extra StrengthTeva Canada Limited
Methoxisal-C 1/2Teva Canada Limited
Methoxisal-C 1/4Teva Canada Limited
Methoxisal-C 1/8Teva Canada Limited
Midol Night-timeBayer Inc Consumer Care
Motrin Platinum Muscle and BodyMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Muscle & Back Pain Asa 325 Mg Methocarbamol 400 Mg & Acetylsalicylic Acid 325 mgVita Health Products Inc
Muscle & Back Pain ReliefPendopharm Division Of De Pharmascience Inc
Muscle & Back Pain Relief - 8Vita Health Products Inc
Muscle & Back Pain Relief CapletsJamp Pharma Corporation
Muscle & Back Pain Relief Extra StrengthPendopharm Division Of De Pharmascience Inc
Muscle & Back Pain Relief With IbuprofenTeva Canada Limited
Muscle & Back Pain Relief-8Pharmascience Inc
Muscle and Back Pain Platinum ReliefVita Health Products Inc
Muscle and Back Pain ReliefTeva Canada Limited
Muscle and Back Pain Relief - 8 TabletsPharmetics (2011) Inc
Muscle and Back Pain Relief CapletsJamp Pharma Corporation
Muscle and Back Pain Relief Extra StrengthTeva Canada Limited
Muscle and Back Pain Relief Regular Strength TabletsPharmetics (2011) Inc
Muscle and Back Pain Relief With AsaTechnilab Pharma Inc.
Muscle and Back Pain Relief With Asa Extra StrengthTechnilab Pharma Inc.
Muscle and Back Pain Relief-8Teva Canada Limited
Muscle Relaxant and AnalgesicTechnilab Pharma Inc.
Muscle Relaxant and Analgesic CapletsInternational Pharmaceutical Generics Ltd
Muscle Relaxant and Back Pain Relief Extra Strength TabletsPharmetics (2011) Inc
Muscle Relaxant and Back Pain Relief Regular Strength TabletsPharmetics (2011) Inc
Nighttime Body PainVita Health Products Inc
Platinum Muscle and Back Pain ReliefVita Health Products Inc
Regular Strength Analgesic & Muscle Relaxant CapletsTeva Canada Limited
Regular Strength Tylenol Back PainMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Regular Strength Tylenol Body Pain NightMcneil Consumer Healthcare Division Of Johnson & Johnson Inc
Relaxophen CapletsTanta Pharmaceuticals Inc
Robax PlatinumPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
RobaxacetPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxacet Extra StrengthPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxacet TabletsWyeth Consumer Healthcare Inc.
Robaxacet-8Pfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal C 1/2Pfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal C 1/4Pfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal C-1/8 TabletsWyeth Consumer Healthcare Inc.
Robaxisal CapletsWyeth Consumer Healthcare Inc.
Robaxisal Extra StrengthPfizer Consumer Healthcare A Division Of Pfizer Canada Inc
Robaxisal TabletsWyeth Consumer Healthcare Inc.
Soulagement Des Douleurs Musculaires & Courbatures Extra FortPharmalab Inc.
Spasmhalt-8Pendopharm Division Of De Pharmascience Inc
Spasmhalt-asa-8Pendopharm Division Of De Pharmascience Inc
Summit UltraPendopharm Division Of De Pharmascience Inc
Super Extra Strength Aspirin BackacheBayer Inc Consumer Care
SaltsNot Available
Categories
UNII125OD7737X
CAS number532-03-6
WeightAverage: 241.2405
Monoisotopic: 241.095022595
Chemical FormulaC11H15NO5
InChI KeyGNXFOGHNGIVQEH-UHFFFAOYSA-N
InChI
InChI=1S/C11H15NO5/c1-15-9-4-2-3-5-10(9)16-6-8(13)7-17-11(12)14/h2-5,8,13H,6-7H2,1H3,(H2,12,14)
IUPAC Name
2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate
SMILES
COC1=CC=CC=C1OCC(O)COC(N)=O
Pharmacology
IndicationFor use as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions.
Structured Indications
PharmacodynamicsMethocarbamol is a central muscle relaxant for skeletal muscles, used to treat spasms. It is structurally related to guaifenesin. Methocarbamol's exact mechanism of causing skeletal muscle relaxation is unknown. It is thought to work centrally, perhaps by general depressant effects. It has no direct relaxant effects on striated muscle, nerve fibers, or the motor endplate. It will not directly relax contracted skeletal muscles. The drug has a secondary sedative effect.
Mechanism of actionThe mechanism of action of methocarbamol in humans has not been established, but may be due to central nervous system depression. It has no direct action on the contractile mechanism of striated muscle, the motor end plate or the nerve fiber.
TargetKindPharmacological actionActionsOrganismUniProt ID
Carbonic anhydrase 1Proteinno
inhibitor
HumanP00915 details
Related Articles
AbsorptionRapid. Onset of action is about 30 minutes after oral administration.
Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationSmall amounts of unchanged methocarbamol also are excreted in the urine.
Half life1.14-1.24 hours
Clearance
  • 0.2 – 0.8 L/h/kg [healthy]
ToxicitySymptoms of overdose include blurred vision, coma, drowsiness, low blood pressure, nausea, and seizures.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methocarbamol.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methocarbamol.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methocarbamol.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Methocarbamol.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Methocarbamol.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Methocarbamol.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methocarbamol.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methocarbamol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methocarbamol.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methocarbamol.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methocarbamol.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methocarbamol.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Methocarbamol.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methocarbamol.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Methocarbamol.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methocarbamol.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Methocarbamol.Vet Approved
AzelastineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methocarbamol.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Methocarbamol.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methocarbamol.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Methocarbamol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methocarbamol.Approved, Illicit
BrompheniramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Methocarbamol.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methocarbamol.Approved, Investigational
BuprenorphineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methocarbamol.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methocarbamol.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Methocarbamol.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Methocarbamol.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Methocarbamol.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methocarbamol.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methocarbamol.Approved, Illicit, Vet Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methocarbamol.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methocarbamol.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methocarbamol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methocarbamol.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methocarbamol.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methocarbamol.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methocarbamol.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methocarbamol.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methocarbamol.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methocarbamol.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methocarbamol.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methocarbamol.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Methocarbamol.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Methocarbamol.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Methocarbamol.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Clonidine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methocarbamol.Approved, Illicit
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methocarbamol.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methocarbamol.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methocarbamol.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methocarbamol.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methocarbamol.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dapoxetine.Investigational
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Methocarbamol.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methocarbamol.Approved
DesipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Methocarbamol.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methocarbamol.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methocarbamol.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methocarbamol.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methocarbamol.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methocarbamol.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methocarbamol.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methocarbamol.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methocarbamol.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methocarbamol.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methocarbamol.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methocarbamol.Approved, Illicit
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Methocarbamol.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methocarbamol.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methocarbamol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methocarbamol.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methocarbamol.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Methocarbamol.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Efavirenz.Approved, Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methocarbamol.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Entacapone.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when Eperisone is combined with Methocarbamol.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methocarbamol.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methocarbamol.Approved
EthanolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methocarbamol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methocarbamol.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methocarbamol.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methocarbamol.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Methocarbamol.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Methocarbamol.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Methocarbamol.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methocarbamol.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methocarbamol.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methocarbamol.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methocarbamol.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flibanserin.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methocarbamol.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methocarbamol.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methocarbamol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methocarbamol.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methocarbamol.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methocarbamol.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fluticasone Propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Methocarbamol.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Methocarbamol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methocarbamol.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methocarbamol is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methocarbamol.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Methocarbamol.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methocarbamol.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methocarbamol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methocarbamol.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methocarbamol.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methocarbamol.Approved
HydrocodoneMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methocarbamol.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Indalpine.Investigational, Withdrawn
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methocarbamol.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methocarbamol.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methocarbamol.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methocarbamol.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methocarbamol.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methocarbamol.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methocarbamol.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methocarbamol.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methocarbamol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methocarbamol.Illicit
LoratadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methocarbamol.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methocarbamol.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Methocarbamol.Investigational
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methocarbamol.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Maprotiline.Approved
MeclizineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Methocarbamol.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methocarbamol.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Methocarbamol.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methocarbamol.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methocarbamol.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methocarbamol.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methocarbamol.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methocarbamol.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methocarbamol.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Methocarbamol.Illicit, Withdrawn
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methocarbamol.Approved
MethotrimeprazineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methocarbamol.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methocarbamol.Approved
MetyrosineMethocarbamol may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methocarbamol.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Investigational
MirtazapineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methocarbamol.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methocarbamol.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methocarbamol.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methocarbamol.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methocarbamol.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methocarbamol.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methocarbamol.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methocarbamol.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methocarbamol.Approved, Illicit
OrphenadrineMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Methocarbamol.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methocarbamol.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methocarbamol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methocarbamol.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methocarbamol.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methocarbamol.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methocarbamol.Approved
ParaldehydeMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Paroxetine.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methocarbamol.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methocarbamol.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
PerazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Methocarbamol.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methocarbamol.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methocarbamol.Approved
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methocarbamol.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Methocarbamol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Methocarbamol.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methocarbamol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methocarbamol.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pomalidomide.Approved
PramipexoleMethocarbamol may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Methocarbamol.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Methocarbamol.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methocarbamol.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methocarbamol.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methocarbamol.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methocarbamol.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methocarbamol.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Promethazine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methocarbamol.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methocarbamol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Methocarbamol.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methocarbamol.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Methocarbamol.Investigational
PyridostigmineThe therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Methocarbamol.Approved
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methocarbamol.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methocarbamol.Approved
RacloprideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methocarbamol.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methocarbamol.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methocarbamol.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methocarbamol.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Methocarbamol.Vet Approved
RopiniroleMethocarbamol may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methocarbamol.Approved
RotigotineMethocarbamol may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methocarbamol.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methocarbamol.Experimental
Sage 547The risk or severity of adverse effects can be increased when Methocarbamol is combined with Sage 547.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methocarbamol.Approved, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Methocarbamol.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methocarbamol.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
StiripentolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methocarbamol.Approved
SuvorexantMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methocarbamol.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Methocarbamol.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Methocarbamol.Investigational
ThalidomideMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methocarbamol.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methocarbamol.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methocarbamol.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methocarbamol.Approved
TiagabineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tiapride.Investigational
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Methocarbamol.Vet Approved
TizanidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methocarbamol.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methocarbamol.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methocarbamol.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methocarbamol.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methocarbamol.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Methocarbamol.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methocarbamol.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methocarbamol.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methocarbamol.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Triprolidine.Approved
Uc1010The risk or severity of adverse effects can be increased when Methocarbamol is combined with Uc1010.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methocarbamol.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Venlafaxine.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Vigabatrin.Approved
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Methocarbamol.Approved
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Methocarbamol.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methocarbamol.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methocarbamol.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Methocarbamol.Vet Approved
ZolpidemMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methocarbamol.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Methocarbamol.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methocarbamol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take without regard to meals.
References
Synthesis ReferenceNot Available
General References
  1. Sica DA, Comstock TJ, Davis J, Manning L, Powell R, Melikian A, Wright G: Pharmacokinetics and protein binding of methocarbamol in renal insufficiency and normals. Eur J Clin Pharmacol. 1990;39(2):193-4. [PubMed:2253675 ]
External Links
ATC CodesM03BA53M03BA03M03BA73
AHFS Codes
  • 12:20.00
PDB EntriesNot Available
FDA labelDownload (121 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9638
Blood Brain Barrier+0.5747
Caco-2 permeable-0.6689
P-glycoprotein substrateNon-substrate0.6452
P-glycoprotein inhibitor INon-inhibitor0.9411
P-glycoprotein inhibitor IINon-inhibitor0.8887
Renal organic cation transporterNon-inhibitor0.9105
CYP450 2C9 substrateNon-substrate0.8431
CYP450 2D6 substrateNon-substrate0.7658
CYP450 3A4 substrateNon-substrate0.606
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.9302
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9066
CYP450 3A4 inhibitorNon-inhibitor0.9338
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9542
Ames testNon AMES toxic0.5776
CarcinogenicityNon-carcinogens0.9406
BiodegradationNot ready biodegradable0.8358
Rat acute toxicity2.2930 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.984
hERG inhibition (predictor II)Non-inhibitor0.9411
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Marsam pharmaceuticals llc
  • Watson laboratories inc
  • Baxter healthcare corp anesthesia critical care
  • Ferndale laboratories inc
  • Forest laboratories inc
  • Able laboratories inc
  • American therapeutics inc
  • Ascot hosp pharmaceuticals inc div travenol laboratories inc
  • Clonmel healthcare ltd
  • Heather drug co inc
  • Hetero drugs ltd
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Lannett co inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Nylos trading co inc
  • Pharmeral inc
  • Pioneer pharmaceuticals inc
  • Purepac pharmaceutical co
  • Roxane laboratories inc
  • Sandoz inc
  • Solco healthcare us llc
  • Solvay pharmaceuticals
  • Superpharm corp
  • Tablicaps inc
  • Upsher smith laboratories inc
  • Vintage pharmaceuticals inc
  • West ward pharmaceutical corp
  • Schwarz pharma inc
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntramuscular; Intravenous100 mg/mL
Injection, solutionIntramuscular; Intravenous1000 mg/10mL
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, film coatedOral500 mg/1
LiquidIntramuscular; Intravenous100 mg
TabletOral
InjectionIntramuscular; Intravenous100 mg/mL
TabletOral500 mg
Tablet, film coatedOral750 mg/1
TabletOral750 mg
Prices
Unit descriptionCostUnit
Robaxin-750 750 mg tablet2.48USD tablet
Robaxin 100 mg/ml vial2.2USD ml
Robaxin-750 tablet1.99USD tablet
Robaxin 500 mg tablet1.68USD tablet
Methocarbamol powder0.95USD g
Methocarbamol 750 mg tablet0.49USD tablet
Methocarbamol 500 mg tablet0.38USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point93 °CPhysProp
water solubility7200 mg/L (at 25 °C)CHEM INSPECT TEST INST (1992)
logP0.61CHEM INSPECT TEST INST (1992)
Predicted Properties
PropertyValueSource
Water Solubility4.21 mg/mLALOGPS
logP0.63ALOGPS
logP0.45ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)13.6ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area91.01 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity59.07 m3·mol-1ChemAxon
Polarizability24.28 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anisoles. These are organic compounds containing a methoxybenzene or a derivative thereof.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenol ethers
Direct ParentAnisoles
Alternative Parents
Substituents
  • Anisole
  • Alkyl aryl ether
  • Secondary alcohol
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Reversible hydration of carbon dioxide. Can hydrates cyanamide to urea.
Gene Name:
CA1
Uniprot ID:
P00915
Molecular Weight:
28870.0 Da
References
  1. Parr JS, Khalifah RG: Inhibition of carbonic anhydrases I and II by N-unsubstituted carbamate esters. J Biol Chem. 1992 Dec 15;267(35):25044-50. [PubMed:1460006 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23